SolarCity Has a Big Problem On Its Hands

//
Categories
Image source: Getty Images. If you need more proof that Tesla Motors ‘(NASDAQ: TSLA)  offer to buyout SolarCity (NASDAQ: SCTY) is a bailout, look no further than SolarCity’s latest “Solar Bonds” offering. The company just filed to sell $124 million of 18-month solar bonds with a 6.5% interest rate, which is higher than any rate...
Read More →

Alpha From Equal-Weighting: A Look At Energy

Through the first four versions of this article, I have shown that equal-weighting four separate sectors – consumer staples, healthcare, financials, and materials – would have meaningfully outperformed capitalization-weighting those same sectors over the trailing decade. This discussion is likely very valuable to some Unique Finance readers as $41B is allocated to those four sector...
Read More →

Berkshire Boosts Apple Stake 55%

Apple – Warren Buffett’s Berkshire Hathaway (BRK.A/BRK.B) started investing in Apple (NASDAQ:AAPL) this year and added during the past quarter. Today, they own a $1.5 billion position. This position could be impacted by the rollout of new iPhones next month as well as potential federal antitrust litigation. For more on Berkshire’s stake in Apple, you...
Read More →

ETFs Are Mis-Priced

Preamble Exchange traded funds, at their onset, provided new and valuable ingress for investors. Daily liquidity is an additive feature for investors, and the financial instruments made access to passive market exposures attainable at low expense. Some of the larger, and broader-based ETFs still provide that utility. However, the more than 500 net new ETFs...
Read More →

Too Systemic To Fail

Editor’s note: This article was originally published on August 21, 2016 by James Hamilton here. Bryan Kelly at the University of Chicago, Hanno Lustig at Stanford and Stijn van Nieuwerburgh at NYU had an interesting paper in the June issue of American Economic Review that used option prices to measure the magnitude of the implicit...
Read More →

Wall Street Breakfast: Pfizer To Buy Medivation For $14B

Pfizer has agreed to acquire Medivation (NASDAQ:MDVN) for $14B, with Pfizer (NYSE:PFE) beating out rivals Celgene (NASDAQ:CELG), Gilead (NASDAQ:GILD), Sanofi (NYSE:SNY), Merck (NYSE:MRK) and AstraZeneca (NYSE:AZN). Medivation makes the leading prostate cancer drug, Xtandi, which is expected to generate $5.7B in annual revenue by 2020. Economy European shares and U.S. stock futures were lower at...
Read More →

Can The Brazilian Rally Continue?

The Brazilian stock market has experienced an impressive run. The iShares MSCI Brazil Capped ETF (NYSEARCA:EWZ) is up by 67% year-to-date, which is far better performance when compared to its emerging markets peers, not to mention the developed share markets. The iShares MSCI Emerging Markets ETF (NYSEARCA:EEM) is up by 17%, the VanEck Vectors Russia...
Read More →